Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cyclopharm Limited ( (AU:CYC) ) has shared an update.
Cyclopharm Limited announced that all resolutions proposed at its Annual General Meeting on May 30, 2025, were successfully passed. This includes approvals related to remuneration reports, director re-elections, and performance rights grants, which reflect strong shareholder support and may positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited operates in the molecular imaging industry, offering products such as Technegas, CycloPET, and Ultralute. The company focuses on providing advanced medical imaging solutions, particularly in nuclear medicine, to enhance diagnostic capabilities.
Average Trading Volume: 99,631
Technical Sentiment Signal: Sell
Current Market Cap: A$134.5M
Learn more about CYC stock on TipRanks’ Stock Analysis page.